Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Increase in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large increase in short interest in November. As of November 15th, there was short interest totalling 77,000 shares, an increase of 40.8% from the October 31st total of 54,700 shares. Based on an average daily volume of 337,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 5.8% of the shares of the stock are sold short.

Sonoma Pharmaceuticals Stock Performance

NASDAQ:SNOA remained flat at $2.79 on Friday. 36,732 shares of the company’s stock were exchanged, compared to its average volume of 201,845. The stock’s 50-day simple moving average is $2.90 and its two-hundred day simple moving average is $1.54. Sonoma Pharmaceuticals has a 52 week low of $2.52 and a 52 week high of $9.37. The stock has a market cap of $3.74 million, a P/E ratio of -0.56 and a beta of 1.38.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.